296 related articles for article (PubMed ID: 18559788)
1. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
[No Abstract] [Full Text] [Related]
2. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
Dermatology; 2008; 217(4):380. PubMed ID: 18849606
[No Abstract] [Full Text] [Related]
3. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
[No Abstract] [Full Text] [Related]
4. Pyoderma gangrenosum possibly triggered by adalimumab.
Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
[No Abstract] [Full Text] [Related]
5. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab-induced lupus erythematosus.
Martín JM; Ricart JM; Alcácer J; Rausell N; Arana G
Lupus; 2008 Jul; 17(7):676-8. PubMed ID: 18625641
[TBL] [Abstract][Full Text] [Related]
7. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
[No Abstract] [Full Text] [Related]
8. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
9. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
10. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
[No Abstract] [Full Text] [Related]
11. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare?
Aslanidis S; Pyrpasopoulou A; Douma S; Petidis K
Arthritis Rheum; 2008 Jan; 58(1):327-8. PubMed ID: 18163500
[No Abstract] [Full Text] [Related]
12. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis.
Dascalu C; Mrejen-Shakin K; Bandagi S
J Clin Rheumatol; 2010 Jun; 16(4):172-4. PubMed ID: 20511978
[TBL] [Abstract][Full Text] [Related]
13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
14. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium chelonae infection associated with adalimumab therapy.
Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
[No Abstract] [Full Text] [Related]
16. Adalimumab-induced asthma.
Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
[No Abstract] [Full Text] [Related]
17. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
18. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab-associated pulmonary fibrosis reply.
Huggett MT; Armstrong R
Rheumatology (Oxford); 2007 Aug; 46(8):1379-80; author reply 1379. PubMed ID: 17553912
[No Abstract] [Full Text] [Related]
20. Pyoderma gangrenosum induced by adalimumab in a seropositive rheumatoid arthritis patient: a paradoxical effect of adalimumab?
Tan Y; Kavaklieva S; Wood F
Rheumatology (Oxford); 2021 Aug; 60(8):e288-e289. PubMed ID: 33836074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
